Kloref

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kloref

Quick Facts

Property	Description
Active Ingredients	Betaine Hydrochloride, Potassium Hydrogencarbonate
Form	Effervescent Tablets (for oral solution)
Pharmacological Class	Electrolyte Replenisher, Mineral Supplement
Origin	Synthetic/Derived

Defining Kloref: Classification and Identity

Kloref is classified as a combination medicinal product and is supplied as a Prescription-Only Medicine (Rx) in many jurisdictions. It functions primarily as an electrolyte replenisher and mineral supplement, placing it within the therapeutic category dedicated to correcting critical mineral and fluid imbalances. The fundamental role of this class of medicine is to substitute and restore key minerals that the body has depleted, aligning with the broader classification of mineral supplements.

Dual Composition and Dosage Form

Kloref's composition features two distinct active ingredients: Betaine Hydrochloride and Potassium Hydrogencarbonate (Potassium Bicarbonate). It is supplied as effervescent tablets, a dosage form for patients with swallowing difficulties, as they dissolve to form an oral solution. The inclusion of Potassium Hydrogencarbonate provides a source of alkalinity alongside the essential Potassium ion (K^+). This combination provides both potassium and chloride, addressing the requirement for maintaining a coordinated electrolyte balance, particularly when potassium deficiency is accompanied by chloride loss.

General Purpose: Electrolyte Equilibrium

The primary general purpose of Kloref is to restore and sustain electrolyte equilibrium, specifically focusing on the balance of potassium and chloride ions. The concentration of potassium ions is essential for maintaining the electrical potential across cell membranes, which impacts nerve impulse transmission and muscle function, including the heart's rhythm. By providing a controlled source of these key minerals, Kloref supports vital physiological functions, ensuring the necessary internal stability for core bodily processes.

What side effects are possible with Kloref?

The safety characteristics of Kloref, which contains an oral potassium salt, are primarily linked to systemic potassium management and the potential for irritation within the Gastrointestinal (GI) System, as classified by regulatory authorities.

Official Adverse Reactions and Frequency

The most common adverse reactions reported in official labeling involve Gastrointestinal Disorders, including nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These effects are frequently observed with oral potassium salts.

Less common, or rare, adverse reactions that have been reported include skin rash and severe structural injuries to the GI tract.

Serious Adverse Reactions and Safety Constraints

Hyperkalemia (high potassium levels in the blood) is documented as the most critical serious adverse reaction, with the potential for abnormal heart rhythms (cardiac arrhythmias) and fatal cardiovascular events. Rare but severe Gastrointestinal Complications—such as obstruction, bleeding, ulceration, and perforation—have also been reported in regulatory documents.

Population-Specific Safety Considerations

The risk of developing severe hyperkalemia is substantially higher in patients with impaired renal function, as the kidneys are essential for potassium excretion. Official guidance advises cautious dose selection in older adults due to the higher likelihood of decreased kidney function in this population, and notes increased risk for patients with cirrhosis.

Safety is also constrained by high-level drug interaction patterns: the concurrent use of Kloref with certain medications, such as potassium-sparing diuretics and RAAS inhibitors (like ACE inhibitors), is associated with a significantly increased risk of severe hyperkalemia, as explicitly documented in government safety labels.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Kloref, a potassium supplement, is documented in regulatory labeling to primarily result in hyperkalemia, or dangerously high levels of potassium in the blood. Mild or moderate hyperkalemia is often asymptomatic, but the condition can escalate rapidly, requiring immediate emergency response.

Documented Overdose Manifestations

Officially recognized clinical signs and symptoms of overdose include disturbances in the neuromuscular and cardiovascular systems. These manifestations are documented in government regulatory sources to include muscle weakness, listlessness, unusual tiredness, and feelings of paresthesia. Gastrointestinal symptoms such as nausea, vomiting, and abdominal pain may also be present.

Severe Outcomes and Emergency Action

Severe hyperkalemia carries the risk of life-threatening cardiotoxicity. Regulatory documents describe the potential for cardiac arrest, fatal arrhythmias, complete heart block, and muscular or respiratory paralysis. Because of these severe outcomes, official guidance mandates that individuals seek immediate medical attention upon any suspicion of overdose.

Overdose risk is noted as significantly increased in those with severe renal impairment or acute dehydration. Management, as described in official prescribing information, requires continuous cardiac monitoring and specific supportive treatment procedures, such as the administration of calcium or insulin/dextrose infusions, to manage the resulting hyperkalemia.

Therapeutic Uses of Kloref

What Kloref Treats: Main Uses and Benefits

Kloref is commonly used to help manage or prevent low blood levels of potassium (hypokalemia). This medication is utilized where additional symptomatic support is needed due to this mineral imbalance. It is primarily used to address symptoms related to systemic imbalance that may become intense or disruptive, such as muscle weakness, painful cramping, and irregularities in heart rhythm.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as those associated with conditions marked by increased physiological stress or the need for supportive treatment during certain medication regimens. By helping to restore potassium, Kloref may assist with maintaining functional stability and contributes to day-to-day comfort. Kloref is considered relevant for easing symptoms that interfere with daily comfort.

Quick Fact: Relevant for Muscular and Cardiac Strain

Regulatory References

FDA Drug Label via DailyMed

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Kloref (Potassium Chloride) is a medicine used to treat or prevent low potassium levels (hypokalaemia). Official regulatory documents define clear populations who must not use the medicine due to the risk of dangerously high potassium levels (hyperkalaemia), which can cause cardiac arrest.

Classification	Population Restriction
Contraindicated (Must not use)	Hyperkalaemia (pre-existing high potassium levels).
	Concurrent use of Potassium-Sparing Diuretics (e.g., amiloride, spironolactone, triamterene).
	Severe Renal Insufficiency with significantly reduced urine output.
	Untreated Addison's Disease (adrenocortical insufficiency).
	Gastrointestinal Obstruction or severe pathological conditions of the GI tract.
Restricted/Special Caution	Patients with Impaired Renal Function (close monitoring required).
	Older Adults (due to potentially reduced kidney function).
	Concurrent use of certain medications that increase potassium, such as ACE Inhibitors (monitoring essential).

Use of Kloref is generally permitted for patients requiring potassium supplementation under medical supervision. For pregnant and breastfeeding individuals, use is typically acceptable when clinically indicated, as potassium is a normal body component, but should only be done with medical oversight.

What should I know about interactions with other medicines?

Kloref, which contains potassium, carries a primary risk of drug interactions related to an increase in blood potassium levels, a condition known as hyperkalemia. This risk is clinically significant when Kloref is taken with other medicines that also affect the body's potassium balance.

Medicines and Products to Avoid

Potassium-Sparing Diuretics: The concomitant use of Kloref with medicines such as spironolactone, triamterene, and amiloride is generally avoided or sometimes contraindicated due to the high risk of severe hyperkalemia. These medicines reduce the excretion of potassium, causing it to accumulate when combined with Kloref.
Aldosterone Antagonists: This class of medicines, which includes some of the potassium-sparing diuretics, also impairs potassium excretion and should be avoided or used with caution.
Potassium-Containing Salt Substitutes: Since these products add extra potassium, using them alongside Kloref significantly increases the risk of hyperkalemia and should be avoided.

Close Monitoring Required

Cardiac Glycosides (e.g., Digoxin): If the combinations listed above cannot be avoided and the patient is concurrently taking a cardiac glycoside, the interaction is considered contraindicated due to an elevated, potentially life-threatening risk of cardiac complications and arrest from hyperkalemia.
ACE Inhibitors and ARBs: Medicines used for blood pressure, such as Angiotensin-Converting Enzyme (ACE) inhibitors (e.g., enalapril) and Angiotensin Receptor Blockers (ARBs) (e.g., losartan), can also cause potassium retention. Use with Kloref requires close and frequent monitoring of blood potassium levels.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Certain NSAIDs may also contribute to potassium retention by affecting the kidneys. Combining these with Kloref requires careful clinical assessment.

Mechanism of Action

Stabilization of Cellular Electrophysiology

This domain focuses on the Potassium ion ( K^+), which serves as an essential substrate for the Na^+/ K^+-ATPase pump, the key enzyme regulating the cell membrane's electrical potential. By supplying K^+ to the plasma, the mechanism facilitates the re-establishment of the electrochemical gradient. This action directly influences cardiac electrophysiology and neuromuscular excitability, promoting the stabilization of electrophysiological processes in excitable tissues.

Regulation of Systemic Acid-Base Parameters

This mechanism engages the anionic components, Bicarbonate ( HCO3^-) and Chloride ( Cl^-), to influence systemic chemical balance. The HCO3^- acts as an immediate physiological buffer of hydrogen ions ( H^+), while the Cl^- ion supports renal electrolyte processes required for the regulation of renal K^+ handling and extracellular fluid tonicity.

Co-delivery of Potassium with Multiple Anions

Kloref's action involves the co-delivery of K^+ with both the buffering anion and the co-regulating anion. This combined mechanism facilitates K^+ ion movement through the presence of multiple anion co-factors, contributing to the maintenance of electrolyte and acid-base homeostatic processes.

Dosage and Administration Information

How to Use Kloref: Administration Guidelines

This section details the usage and dosing instructions for Kloref Effervescent Tablets.

Feature	Instruction
Route of administration	Oral solution, prepared by dissolving the effervescent tablet.
Dosing schedule	For Prophylaxis, the dose is typically 20 mEq daily. For Treatment, the regimen generally involves 1 to 2 tablets, three to four times daily.
Timing in relation to meals	The prepared solution must be taken with meals or immediately after eating.
Preparation requirements	The tablet must be completely dissolved in water before consumption.
Age-group administration rules	Dosing for Older Adults is typically the same as for adults; dosage for Children is determined by body weight and indication.
Special procedural conditions	The prepared oral solution must be sipped slowly over a period of 5 to 10 minutes, a standard procedural condition for this class of medicine. The tablet must not be swallowed whole.

Procedural Structure

The administration protocol requires the preparation of a liquid form for ingestion. The daily requirement is satisfied through divided doses, ensuring a sustained delivery of the active ingredients throughout the day. This structure ensures that the amount is administered via the correct oral route under specific consumption conditions, including meal timing and slow ingestion.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kloref

Evidence for Use in Low Potassium Levels (Hypokalemia)

Regulatory review for medicines like Kloref is based on research concerning Randomized Controlled Trials (RCTs) and Systematic Reviews focused on oral potassium replacement therapy. These studies were conducted during periods of increased symptom activity associated with low potassium. Researchers examined the use of oral potassium salts in adults who had been diagnosed with mild to moderate hypokalemia, a condition characterized by low blood potassium levels.

In these research scenarios, studies primarily monitored the change in serum potassium concentration, which is a key biomarker reflecting physiological strain or stress. Studies reported that the administration of oral potassium salts was associated with measurable increases in this concentration, with observed potassium levels reported in the studies.

Understanding the Study Landscape and Endpoints

Research explored different study outcomes examined for oral potassium replacement. The focus in many trials was on measuring changes in the biomarker shift (serum potassium level) over defined time intervals. These studies also monitored patient-reported outcomes describing perceived discomfort, particularly outcomes related to physical discomfort like muscle cramps. Findings describe patterns related to outcomes reflecting daily functioning or activity level in settings where mineral imbalance was observed.

What is Still Uncertain About the Research for Kloref

Long-term observation and the duration of studied effects are not fully established, and follow-up durations in the most rigorous comparative trials were often modest. A key limitation is the lack of extensive large-scale RCTs conducted specifically on the unique combination of Potassium Hydrogencarbonate and Betaine Hydrochloride found in Kloref. Consequently, regulatory reliance is placed heavily on the general class evidence for the potassium ion itself. Furthermore, the study of the link between observed biomarker changes and sustained, long-term functional outcomes remains an area where data are insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Kloref (FAQ)

Q: Is it better to take Kloref with or without food?

A: Official product information indicates that Kloref is typically administered with meals or immediately after eating. This approach is generally advised to mitigate the potential for gastrointestinal irritation associated with oral potassium salts.

Q: What happens if you take alcohol while using Kloref?

A: Regulatory documents typically do not provide explicit guidance regarding the consumption of alcohol while using Kloref. Any questions or concerns regarding alcohol consumption while taking this medication should be directed to a qualified healthcare professional.

Q: Is it normal to feel a mild burning sensation in the stomach after taking Kloref?

A: Commonly reported side effects for Kloref, as listed in the official safety information, include gastrointestinal issues like nausea, vomiting, and abdominal pain or discomfort. Persistent or severe symptoms of this nature warrant consultation with a healthcare provider.

Q: Why might a doctor prescribe the effervescent form of Kloref over a standard tablet?

A: Kloref is supplied as an effervescent tablet, which is designed to be dissolved in water before consumption. This dosage form is often preferred by healthcare providers for patients who have difficulty swallowing solid tablets or capsules.

Q: Are there any known issues with taking Kloref on an empty stomach?

A: Yes. The administration guidance indicates that Kloref is to be taken with meals or immediately after eating. Failure to follow this direction may increase the potential for gastrointestinal irritation and discomfort.

Q: Is Kloref the same as ibuprofen, or is it different?

A: Kloref is classified as an electrolyte replenisher and mineral supplement, primarily used to correct low potassium levels (hypokalemia). It belongs to a different drug class than ibuprofen, which is a Non-Steroidal Anti-Inflammatory Drug (NSAID) used for pain and inflammation.

Q: Does Kloref treat the cause of the pain or just mask the symptoms?

A: Kloref's therapeutic indication, according to regulatory documents, is the prevention and treatment of low potassium levels (hypokalemia). It is not indicated as a general treatment for pain symptoms.

Q: What should I do if I miss a dose of Kloref?

A: Instructions for a missed dose are outlined in the official prescribing information, which typically advises a specific procedure for when to take the dose and when to skip it to avoid a double dose. Refer to the patient information leaflet for the specific guidance.

Q: Can Kloref cause drowsiness or make you feel sleepy?

A: Drowsiness or sleepiness are not listed as common side effects in the official safety information for Kloref. Regulatory documents also report no specific effects on the ability to drive or operate machinery have been noted.

Q: Do you need a prescription to get Kloref?

A: Yes, Kloref is designated as a Prescription-Only Medicine (POM or Rx) in many jurisdictions where it is available. It is supplied under the supervision of a qualified healthcare professional.

Q: Are there any common supplements that interact with Kloref?

A: A significant interaction caution is specifically noted for potassium-containing salt substitutes. Using these products alongside Kloref is discouraged as they can greatly increase the risk of developing dangerously high potassium levels, known as hyperkalemia.

Q: What signs indicate that I might be having a serious reaction to Kloref?

A: Signs of a serious adverse reaction, particularly severe hyperkalemia (high potassium), may include an irregular or rapid heartbeat, feelings of muscle weakness, and tingling or numbness. The onset of these symptoms warrants immediate medical evaluation.

Q: What are the signs of a Kloref overdose?

A: The signs of an overdose are related to symptoms of severe hyperkalemia, which include serious changes in heart rhythm (cardiac arrhythmias), extreme muscle weakness, and confusion. This condition is considered a medical emergency.

Q: Can Kloref be crushed or split if the tablet is too large?

A: The official method of administration specifies that the effervescent tablet must be completely dissolved in water to form an oral solution. The tablet itself is not to be swallowed whole, crushed, or split.

Q: Is it safe to take Kloref if I have a history of ulcers?

A: Official warnings note that severe gastrointestinal conditions, such as obstruction or ulceration, can be risks or contraindications. The decision to use Kloref in individuals with a history of such conditions is based on a clinical assessment by a healthcare provider.

Q: What are the restrictions for driving or operating machinery after taking Kloref?

A: Regulatory documents specifically state that Kloref is not expected to have any effects on a patient's ability to drive or operate machinery.

Q: Does Kloref have a risk of dependence or addiction?

A: As an electrolyte replenisher used for mineral balance, Kloref is not classified as a medicine that carries a risk of physical dependence or addiction.

How should Kloref be stored and disposed of?

Kloref (Betaine Hydrochloride and Potassium Hydrogencarbonate Effervescent Tablets) must be stored according to specific environmental requirements to maintain product stability and integrity.

Storage Requirements

Storage Factor	Official Requirement
Temperature	Store at a temperature below 25 C
Environment	Keep in a dry place and protected from light
Container	Must be stored in the original container and box
Shelf Life	Stable for 24 months when stored correctly

The product must be kept out of the sight and reach of children. Adherence to these conditions is essential for the medicine to remain stable throughout its 24-month shelf life. For disposal, unused or expired Kloref must be managed according to local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Greece

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z